Argent BioPharma Limited
RGTLF
$0.0599
$0.011423.51%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -99.28% | -99.29% | -60.31% | -61.28% | -77.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.28% | -99.29% | -60.31% | -61.28% | -77.68% |
| Cost of Revenue | -99.30% | -99.25% | 8.48% | 5.83% | -63.45% |
| Gross Profit | -99.15% | -99.16% | -416.33% | -408.73% | -94.18% |
| SG&A Expenses | 29.48% | 32.50% | 52.94% | 49.18% | -22.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 9,182.35% | 9,441.18% | -20.74% | -17.73% | -100.32% |
| Total Operating Expenses | 15.86% | 18.56% | 26.60% | 23.48% | -29.14% |
| Operating Income | -25.76% | -28.70% | -35.26% | -31.91% | 12.82% |
| Income Before Tax | -71.42% | -75.42% | -2.51% | 0.01% | 36.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -71.42% | -75.42% | -2.51% | 0.01% | 36.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -99.75% | -99.75% | -90.78% |
| Net Income | -71.84% | -75.86% | -3.74% | -1.18% | 35.56% |
| EBIT | -25.76% | -28.70% | -35.26% | -31.91% | 12.82% |
| EBITDA | -28.74% | -31.75% | -35.08% | -31.75% | 17.97% |
| EPS Basic | 21.64% | 19.84% | 93.27% | 93.44% | 92.77% |
| Normalized Basic EPS | 48.85% | 47.79% | 93.06% | 93.24% | 87.74% |
| EPS Diluted | 21.64% | 19.84% | 93.34% | 93.50% | 92.77% |
| Normalized Diluted EPS | 48.85% | 47.79% | 93.06% | 93.24% | 87.74% |
| Average Basic Shares Outstanding | 119.41% | 119.41% | 1,441.74% | 1,441.74% | 791.36% |
| Average Diluted Shares Outstanding | 119.41% | 119.41% | 1,441.74% | 1,441.74% | 791.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |